RemeGen Co., Ltd. (HKG:9995)
Hong Kong
· Delayed Price · Currency is HKD 100.10
-4.40 (-4.21%)
Apr 29, 2026, 4:08 PM HKT
RemeGen Revenue
RemeGen had revenue of 656.21M CNY in the quarter ending March 31, 2026, with 24.76% growth. This brings the company's revenue in the last twelve months to 3.38B, up 76.81% year-over-year. In the year 2025, RemeGen had annual revenue of 3.25B with 89.36% growth.
Revenue (ttm)
3.38B CNY
Revenue Growth
+76.81%
P/S Ratio
19.83
Revenue / Employee
1.11M CNY
Employees
3,048
Market Cap
76.21B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 35.43B |
| 3SBio | 19.69B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.29B |
| Akeso | 3.40B |
| Biocytogen Pharmaceuticals (Beijing) | 1.78B |
| Shanghai Junshi Biosciences | 2.78B |
| Shanghai Henlius Biotech | 7.42B |
| WuXi Biologics | 24.25B |
RemeGen News
- 3 months ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 7 months ago - 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China - PRNewsWire
- 9 months ago - RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PRNewsWire
- 9 months ago - RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA - PRNewsWire
- 10 months ago - PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement - Business Wire
- 11 months ago - RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis - PRNewsWire
- 1 year ago - RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China - PRNewsWire
- 1 year ago - Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis - PRNewsWire